2024-03-29T10:22:58Z
https://jkcvhl.com/index.php/jkcvhl/oai
oai:ojs.pkp.sfu.ca:article/8
2022-02-11T11:33:46Z
jkcvhl:ED
"140422 2014 eng "
2203-5826
dc
Editor's note
Cancer and VHL, Journal of Kidney
Dear fellow researchers,
Welcome to the first issue of the Journal of Kidney Cancer and VHL (JKCVHL).
JKCVHL is an open access journal created to fill the vacuum for a specialized journal to disseminate information on the advances in kidney cancer and VHL research. I am confident JKCVHL will fulfil its intended purpose, and will be a leading journal in this field in the days to come.
Christudas Morais, MSc, MPhil, PhD
Editor
Codon Publications
2014-04-21 00:00:00
application/pdf
text/html
https://jkcvhl.com/index.php/jkcvhl/article/view/8
Journal of Kidney Cancer and VHL; Vol. 1 No. 1 (2014): Journal of Kidney Cancer and VHL
eng
Copyright (c) 2015 Journal of Kidney Cancer and VHL
oai:ojs.pkp.sfu.ca:article/127
2023-07-30T12:16:01Z
jkcvhl:ED
"200522 2020 eng "
2203-5826
dc
The Year in Review for Renal Cancer
Vaishampayan, Ulka
Professor of Medicine, Department of Oncology, University of Michigan, 1500 E Medical Center Drive, Ann Arbor MI 48109.
The treatment of kidney cancer has made some remarkable strides over the last few years. Two regimens received Food and Drug Administration (FDA) approval, multiple biomarkers were reported to show promise, and further enhancement and refinement of the prognostic characteristics occurred. The combinations of anti-angiogenic tyrosine kinase inhibitors with immune checkpoint inhibitors have rapidly become the preferred therapies in the front-line setting of advanced renal cancer.
Codon Publications
2020-04-16 00:00:00
application/pdf
text/html
text/xml
https://jkcvhl.com/index.php/jkcvhl/article/view/127
Journal of Kidney Cancer and VHL; Vol. 7 No. 1 (2020): Journal of Kidney Cancer and VHL
eng
Copyright (c) 2020 Ulka Vaishampayan, MD
oai:ojs.pkp.sfu.ca:article/207
2022-03-30T07:11:58Z
jkcvhl:ED
"211014 2021 eng "
2203-5826
dc
Routine Bone Imaging for Metastatic Renal Cell Carcinoma: Is it Time?
Parikh, Mamta
University of California Davis Comprehensive Cancer Center, Sacramento, CA, USA.
Current guidelines by the National Comprehensive Cancer Network recommend that, in addition to routine computed tomography (CT) imaging, bone imaging and brain magnetic resonance imaging (MRI) should be obtained when clinically indicated. In this issue of the Journal of Kidney Cancer and VHL, a systematic literature review of clinical trials of metastatic renal cell carcinoma (mRCC) patients evaluates the incidence of osseous, lymph node, and lung metastases (1). In particular, the analysis by Lin et al focuses on the changes in incidence over time. The study finds that the incidence of bone, lymph node, and lung metastases has increased over time. This increase is significant in osseous metastases specifically. These results lead to two provocative questions. First, why have osseous metastases increased in incidence over time? Second, does this finding warrant a more aggressive and uniform approach to imaging to identify osseous metastases sooner?
Codon Publications
2021-10-04 00:00:00
application/pdf
text/html
text/xml
https://jkcvhl.com/index.php/jkcvhl/article/view/207
Journal of Kidney Cancer and VHL; Vol. 8 No. 4 (2021): Journal of Kidney Cancer and VHL
eng
Copyright (c) 2021 Mamta Parikh
oai:ojs.pkp.sfu.ca:article/221
2023-07-30T12:11:22Z
jkcvhl:ED
"220128 2022 eng "
2203-5826
dc
Spectrum of Presentations and Management Strategies in Renal Angiomyolipoma
Khaddam, Sinan
Division of Hematology and Oncology, Department of Medicine, University of Cincinnati, Cincinnati, OH, USA.
Gulati, Shuchi
Division of Hematology and Oncology, Department of Medicine, University of Cincinnati, Cincinnati, OH, USA.
Renal angiomyolipoma (rAML) occurs rarely sporadically but is commonly encountered in patients with tuberous sclerosis complex and lymphangioleiomyomatosis. rAML is a rare entity, not seen regularly in daily practice; however, is commonly encountered and diagnosed by clinicians who approach and treat kidney masses. Basic knowledge of this entity is necessary to recognize that despite being benign, these tumors can rarely cause deadly complications such as hemorrhage or severe renal dysfunction or may have malignant components associated with them.
Codon Publications
2021-11-29 00:00:00
application/pdf
text/html
text/xml
https://jkcvhl.com/index.php/jkcvhl/article/view/221
Journal of Kidney Cancer and VHL; Vol. 9 No. 1 (2022): Journal of Kidney Cancer and VHL
eng
Copyright (c) 2022 Sinan Khaddam, Shuchi Gulati